20.06.2018
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Green Mining - BRAIN AG and CyPlus GmbH develop disruptive technologies for biological processing of precious metal ores
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/Sustainability
B.R.A.I.N. Biotechnology Research And Information Network AG: Green Mining -
BRAIN AG and CyPlus GmbH develop disruptive technologies for biological
processing of precious metal ores
20.06.2018 / 08:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Green Mining
BRAIN AG and CyPlus GmbH develop disruptive technologies for biological
processing of precious metal ores
* Industrially relevant production of precious metals realized on the
metric ton scale, even after scale-up of bio-based method
* Precious-metal enrichment using microorganisms from the BRAIN
BioArchives
* Expansion of the CyPlus product portfolio for Green Mining
* Market launch of initial products expected in the course of 2019
The bioeconomy company BRAIN AG and CyPlus GmbH have announced the
development of an initial range of market-relevant products for the global
mining industry. This work has been carried out as part of a multi-year
collaboration between the companies in the area of biological ore processing
to extract gold and silver. On the basis of successful laboratory research
up to the 100-liter scale, the partners then succeeded in scaling up the
process to the metric ton level last October, thus reaching an important
milestone in the last stage towards market maturity. The bio-based process
could produce the desired precious metals from ores in industrially relevant
yields, even for throughputs on the metric ton scale. The method is now
being further improved for industrial application and this process is
sufficiently advanced for the partners to expect the market launch of the
first range of products as early as 2019.
The extraction of precious metals from the ores is based on the use of
naturally occurring and enhanced microorganisms from the BRAIN BioArchives.
During the ongoing collaboration, the partners very soon reached the goal of
identifying a variety of microorganisms that, having highly specific
adhesion effects, give the gold and silver-bearing minerals a new physical
property. This effect can be exploited to separate gold or silver
specifically from gangue and enrich it in an integrated process step.
"Our research aims at developing bio-based methods that could offer
innovative and sustainable processes for green mining in global markets for
ore processing," says Stefan Welbers, Senior Vice President and General
Manager of CyPlus GmbH. "For this reason we've continuously kept the
technical requirements and structural conditions in mines in mind. In the
foreseeable future, for example, we'll be able to offer mine operators the
possibility of integrating advanced biotechnological methods into their
current processes without significant investment costs or delays in
operation. In this way, we're expanding our technology portfolio to include
biological components for efficient and eco-friendly processing of precious
metals."
Dr. Guido Meurer, member of the Management Board and Unit Head Producer
Strain Development at BRAIN AG, says: "We're delighted - and proud - that
the BRAIN and CyPlus interdisciplinary team has succeeded in establishing a
groundbreaking biological process for a new processing technology and
developing it to high product maturity in just a few years. With our
processes for Green Mining it will be possible in the future to exploit ore
deposits containing precious metals even in regions where the conventional
processes are out of the question. Green Mining is an increasingly important
issue and an attractive field of business also in view of the increasing
scarcity of raw materials."
The partners have already filed a patent for the bio-based method, which
describes the special microorganisms possessing selectively adhesive
properties that can be used to enrich precious metals from ores.
Under the mining program, BRAIN is also researching into biological
solutions for what is known as Urban Mining, where precious metals are
obtained from side streams and waste streams such as slags, ashes, and
electronic scrap. The BRAIN BioXtractor (see
www.brain-biotech.de/en/bioxtractor) has been established as a demo system
for this purpose.
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN
DE0005203947 / WKN 520394) is one of Europe's leading technology companies
in the field of industrial biotechnology, the core discipline of Bioeconomy.
As such, BRAIN identifies previously untapped, efficient enzymes, microbial
producer organisms or natural substances from complex biological systems
that can be put to industrial use. The innovative solutions and products
developed by help of this "Toolbox of Nature" are successfully applied in
the chemistry, the cosmetics and the food industries. BRAIN's business model
is based on two pillars - BioScience and BioIndustrial. The BioScience
segment comprises its frequently exclusive collaboration business with
industrial partners. BioIndustrial comprises the development and
commercialization of BRAIN's own products and active product components.
Further information is available at www.brain-biotech.de/en.
About CyPlus
CyPlus is a globally established company in cyanides. The Evonik subsidiary
provides innovative products, technologies and services to customers in the
mining, chemical, pharmaceutical, and surface treatment industries. The
company meets the extensive and strict requirements of the international
mining industry as a supplier of cyanides in accordance with the provisions
of the "International Cyanide Management Code" (ICMC). Production sites in
Europe as well as sales and distribution offices on all continents provide
customers swift and reliable service. CyPlus regards itself as a pacesetter
of progress and sustainability. Further information is available at
www.cyplus.com.
BRAIN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
www.brain-biotech.de/en
Media Contact
Thomas Deichmann
Head of Public Relations
Tel.: +49-(0)-6251-9331-72
E-Mail: [email protected]
Investor Relations Contact
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-(0)-6251-9331-16
E-Mail: [email protected]
CyPlus GmbH
Rodenbacher Chaussee 4
63457 Hanau-Wolfgang, Germany
www.cyplus.com
Contact
Frank Ladwig
Marketing Manager
Technologies & Services
Tel.: +49-6181-59-6944
E-Mail: [email protected]
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that could
cause actual results, performance or events to differ materially from those
expressed or implied in such statements. There are numerous factors which
could influence the future performance by and future developments at BRAIN
AG and the BRAIN group of companies. Such factors include, but are not
limited to, changes in the general economic and competitive environment,
risks associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. BRAIN AG does
not undertake any obligation to update or revise any forward-looking
statements.
---------------------------------------------------------------------------
20.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
696921 20.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN